RCELHealthcare · Medical DevicesRCEL Stock Forecast: AVITA Medical, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering AVITA Medical, Inc. hold a median 12-month price target of $9.12 — +97.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 1 Aug 2026 — in the lower half.
RCEL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores AVITA Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own AVITA Medical, Inc. — and when they’d sell — is the membership.
RCEL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RCEL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +97.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 May 2026 | Lake Street | Upgrade | Buy | $3.50 → $6.00 |
| 9 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 5 Mar 2026 | Northland Capital Markets | Initiates | Outperform | — |
| 17 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 26 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 16 Jan 2026 | Lake Street | Maintains | Hold | — |
| 15 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 20 Nov 2025 | BTIG | Upgrade | Neutral | — |
| 7 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 17 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 17 Oct 2025 | Lake Street | Downgrade | Hold | — |
| 15 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 5 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 11 Aug 2025 | Lake Street | Maintains | Buy | — |
| 8 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 6 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RCEL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
AVITA Medical, Inc. (RCEL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −2.5×
- Price / sales
- 1.9×
- Price / book
- −5.8×
- EV / EBITDA
- −4.6×
Cheaper than 86% of US stocks
Cheaper than 55% of US stocks
Cheaper than 96% of US stocks
Cheaper than 78% of US stocks
- Revenue growth (YoY)
- 4.0%
- Earnings growth (YoY)
- 4.0%
- Gross margin
- 81.7%
- Operating margin
- −45.7%
- Net margin
- −62.7%
Higher than 39% of US stocks
Higher than 42% of US stocks
Higher than 92% of US stocks
Higher than 18% of US stocks
Higher than 8% of US stocks
- Return on equity
- 291.8%
- Return on assets
- −40.8%
- Dividend yield
- —
Higher than 99% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
RCEL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RCEL appears on the weeks it earns a place.
Frequently asked questions about RCEL stock
What is the RCEL stock price forecast for 2026-2027?
The 3 Wall Street analysts covering AVITA Medical, Inc. have a median 12-month price target of $9.12, with estimates ranging from $6.03 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RCEL stock a buy right now?
Of the 3 analysts covering AVITA Medical, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AVITA Medical, Inc. 45 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RCEL?
As at 1 Aug 2026, AVITA Medical, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).
Will RCEL stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +97.4% from the last close, and Ticker Nerd's factor model ranks AVITA Medical, Inc. 45 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RCEL stock forecast for 2030?
No analyst covering AVITA Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RCEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.03 to $12 over the next 12 months.
How has RCEL stock performed over the past year?
AVITA Medical, Inc. returned -10.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does AVITA Medical, Inc. do?
Avita Medical Inc. is a global regenerative medicine company that focuses on harnessing the body's innate regenerative ability to address significant unmet medical needs in the field of burns, chronic wounds, and skin rejuvenation therapies.
About AVITA Medical, Inc.
Avita Medical Inc. is a global regenerative medicine company that focuses on harnessing the body's innate regenerative ability to address significant unmet medical needs in the field of burns, chronic wounds, and skin rejuvenation therapies. The company's core product is the RECELL System, an innovative approach designed to enhance the healing of skin ailments and injuries by using a patient's own skin cells. This system stands out for its ability to significantly reduce the need for extensive skin grafting, which is traditionally required in burn treatment, thereby minimizing donor site morbidity and improving patient outcomes. Avita Medical is particularly influential in the healthcare and biotechnology sectors, providing a crucial solution for patients and medical practitioners dealing with burn treatment and epithelial resurfacing procedures. Its technology holds the potential to revolutionize standard care practices due to its minimally invasive application and efficient healing outcomes. With international recognition, the company plays a vital role in advancing the field of regenerative medicine, offering hope through innovations that enhance quality of life for patients with serious skin injuries and conditions.
CEO Mr. Cary G. Vance · 226 employees · United States · https://avitamedical.com